Prothena Presents Positive Clinical Data on Parkinson's and Alzheimer's Treatments at AD/PD 2026

Saturday, Mar 21, 2026 4:07 pm ET1min read
PRTA--

Prothena Corporation presented data on its investigational therapeutics for Parkinson's disease and Alzheimer's disease at the AD/PD 2026 conference. Roche presented data on prasinezumab for Parkinson's disease, including sustained effects on motor progression and biomarkers. Prothena also presented data on BMS-986446 for Alzheimer's disease, highlighting its potential as a treatment. The presentations suggest that both prasinezumab and BMS-986446 may have disease-modifying effects, slowing the progression of the diseases.

Prothena Presents Positive Clinical Data on Parkinson's and Alzheimer's Treatments at AD/PD 2026

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet